Compare PLSM & CCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSM | CCM |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | Israel | China |
| Employees | 63 | N/A |
| Industry | Medical/Dental Instruments | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.3M | 19.0M |
| IPO Year | N/A | 2009 |
| Metric | PLSM | CCM |
|---|---|---|
| Price | $3.42 | $4.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 317.2K | 44.5K |
| Earning Date | 03-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.00 | $3.18 |
| 52 Week High | $12.97 | $6.98 |
| Indicator | PLSM | CCM |
|---|---|---|
| Relative Strength Index (RSI) | 43.00 | 58.89 |
| Support Level | $3.17 | $4.41 |
| Resistance Level | $3.93 | $5.38 |
| Average True Range (ATR) | 0.26 | 0.50 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 31.94 | 67.35 |
Pulsenmore Ltd is an emerging medical device company engaged in the research, development, manufacturing, marketing, and sale of non-invasive portable ultrasound solutions for home use. Its products include the Pulsenmore ES and Pulsenmore FC, along with the early-stage Pulsenmore MC, collectively referred to as Pulsenmore Products, enabling remote ultrasound scans in gynecology and other fields such as pulmonary, cardiology, and urology through telemedicine. The Company operates in a single segment focused on developing and commercializing portable ultrasound technologies, with Israel contributing the majority of its revenue.
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Geographically, the company derives revenue from PRC.